MET and lung cancer: MET exon 14 (METex14) alteration occurs with low frequency in stomach (4.8–7.1%), colorectal (~0–9.3%), and lung cancers (adenocarcinoma, 2.6–3.2%; pulmonary sarcomatoid tumor, 2.6–31.8%; adenosquamous carcinoma, 4–8.2%) [8,9,10].